Skip to main content
Premium Trial:

Request an Annual Quote

Mitsubishi Chemical and Fujitsu to Jointly Develop Genomics-based Drugs- Wall Street Journal

NEW YORK, March 5 – Mitsubishi Chemical has joined forces with Fujitsu, a large Japanese electronics and information technology company, to use genomics data to research and develop pharmaceuticals, the Wall Street Journal reported Monday.

The two firms said in a statement that they hoped to promote genomics-based drugs and personalized medicine to create a "new life science society.” While the alliance has no specific projects yet, a joint task force will hash out the details of the alliance and develop a research focus.

"We have agreed to cooperate in creating new businesses as well as boosting existing businesses by combining biotechnology and information technology, which represent the key to technological development in the 21st century," the firms said in a statement.

Mitsubishi Chemical, the largest producer of chemicals in Japan, has recently shifted its attention to bolstering its life science and biotechnology businesses. Most recently, Mitsubishi acquired the rights to sell HTS Biosystem’s bioanalysis system for protein detection in Japan.

Fujitsu is also working with Daiichi Pharmaceutical and Celestar Lexico-Sciences, a biotech start-up, to develop genomics-based drugs. 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.